-$0.11 Earnings Per Share Expected for Evoke Pharma Inc (EVOK) This Quarter
Analysts expect that Evoke Pharma Inc (NASDAQ:EVOK) will report earnings of ($0.11) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Evoke Pharma’s earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.08). Evoke Pharma reported earnings of ($0.22) per share in the same quarter last year, which would suggest a positive year over year growth rate of 50%. The firm is scheduled to announce its next earnings results on Wednesday, March 6th.
On average, analysts expect that Evoke Pharma will report full-year earnings of ($0.47) per share for the current financial year, with EPS estimates ranging from ($0.48) to ($0.46). For the next fiscal year, analysts forecast that the business will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.83) to ($0.34). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Tuesday, November 13th. The specialty pharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.01).
Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of Evoke Pharma by 5.5% in the fourth quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock valued at $207,000 after buying an additional 4,392 shares during the last quarter. Wambolt & Associates LLC bought a new position in shares of Evoke Pharma in the fourth quarter valued at about $82,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Evoke Pharma in the third quarter valued at about $111,000. 18.60% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ EVOK opened at $2.88 on Wednesday. Evoke Pharma has a 52-week low of $1.85 and a 52-week high of $3.40.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Further Reading: Understanding each part of a balance sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.